Suggested remit - To appraise the clinical and cost effectiveness of carfilzomib with daratumumab and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.
Status In progress
Process STA 2018
ID number 2709

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 02 March 2020 - 30 March 2020
Expected publication 21 April 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 January 2020 In progress, Referred September 23 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance